Can the Histoculture Drug Response Assay Predict the Clinical Results of Chemotherapy in Breast Cancer?.
10.4048/jbc.2007.10.3.193
- Author:
Yong Sik JUNG
1
;
Young Up CHO
;
Young Jin SUH
;
Jeong Soo KIM
;
Se Jeong OH
;
Cheol Wan LIM
;
Moon Bo KIM
;
Heung Kyu PARK
Author Information
1. Department of Surgery, Ajou University, School of Medicine, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Breast cancer;
Chemotherapy;
Histoculture Drug Response Assay (HDRA)
- MeSH:
Antineoplastic Agents;
Breast Neoplasms*;
Breast*;
Doxorubicin;
Drug Therapy*;
Gelatin Sponge, Absorbable;
Humans;
Porifera;
Sensitivity and Specificity
- From:Journal of Breast Cancer
2007;10(3):193-198
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The behavior of invasive carcinomas in human can be very varied with different individual responses to chemotherapy. Individualization is crucial to the optimization of chemotherapy. Therefore, the prediction of a tumor's sensitivity to anticancer agents has been the subject of intensive investigation. In order to investigate the pathobiology of breast cancer, it is necessary to maintain or recreate the characteristics of the three-dimensional architecture of the tissues in culture. In this study, we have evaluated the relationship between the Histoculture Drug Response Assay (HDRA) assessment and chemotherapy responses in breast cancer patients. METHODS: Tumor specimens from 30 patients with breast cancer were evaluated using the HDRA. Tumor tissues were cultured on gelfoam sponge gel in 24-well plates, followed by treatment with a variety of chemotherapeutic agents. All treatments were conducted in triplicate. The sensitivity of a chemotherapy regimen was defined as a tumor inhibition rate (IR) in excess of 30%. Neoadjuvant or palliative chemotherapy for patients, using anthracycline or taxane, was conducted on the basis of the established protocols. The responses to treatments were compared with the results of the HDRA. RESULTS: The mean IR for the combinations of doxorubicin and docetaxel and for FAC and AC were 48, 45, and 36%, respectively. The above partial rate of response to chemotherapy was 81.1%. The sensitivity and specificity of the HDRA assessment, with a 30% inhibition rate, were 81.5 and 66.7%, respectively. The positive and negative response prediction values were 91.7 and 44.4%, respectively. The responses to treatments and the results of the HDRA assessment were not correlated with the expressions of the hormonal receptor or c-erbB2. CONCLUSION: In cases in which the inhibition rate is in excess of 30%, the HDRA assessment yielded a high positive response prediction value. The sensitivity to chemotherapy, as determined by the HDRA, appears to be a good guide for selection in breast cancer patients. Thus the results presented herein should be integrated into future research on the subject.
